Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Asset Writedowns and Impairment (2021 - 2025)

GeneDx Holdings has reported Asset Writedowns and Impairment over the past 5 years, most recently at -$17000.0 for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at -$17000.0 for Q4 2025, down 139.53% from a year ago — trailing twelve months through Dec 2025 was $55000.0 (up 27.91% YoY), and the annual figure for FY2025 was $135000.0, down 25.0%.
  • Asset Writedowns and Impairment for Q4 2025 was -$17000.0 at GeneDx Holdings, down from $29000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for WGSWW hit a ceiling of $174.5 million in Q4 2022 and a floor of -$1.3 million in Q3 2021.
  • Median Asset Writedowns and Impairment over the past 5 years was $279000.0 (2023), compared with a mean of $16.8 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: surged 15652.58% in 2022 and later crashed 139.53% in 2025.
  • GeneDx Holdings' Asset Writedowns and Impairment stood at -$1.1 million in 2021, then surged by 15652.58% to $174.5 million in 2022, then crashed by 99.84% to $279000.0 in 2023, then crashed by 84.59% to $43000.0 in 2024, then crashed by 139.53% to -$17000.0 in 2025.
  • The last three reported values for Asset Writedowns and Impairment were -$17000.0 (Q4 2025), $29000.0 (Q3 2025), and $43000.0 (Q4 2024) per Business Quant data.